2026 Q2 -tulosraportti
19 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
3,89%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·10 min sittenNew week, and Nordnet searched searched and ....searched, aren't there any negative comments about Novo Nordisk. Lo and behold, an enterprise Baptista Research, WTF is Baptista. Is it a basement room with 3 prostitutes and 1 pickpocket, that now proclaims Novo SELL and drives the share price down. I know Nordnet doesn't give a damn if the undersigned pulls the plug and uses for example Saxo Bank in the future, but incredibly tired of the way the information flow uncritically reaches all Nordnet's users. Baptista and my bare ass. Damn what a start to the week !!
·1 t sittenWildly exciting when the first Foundayo prescription figures are published! Novo Nordisk's American rival Eli Lilly has launched its weight loss pill Foundayo in the United Kingdom. The drug is launched for the treatment of severe obesity and type 2 diabetes, Reuters writes. This is the first European market that Foundayo is entering. The launch comes after Eli Lilly had its pill approved on August 10. Novo had already launched its weight loss tablet, the Wegovy pill, in the British market in July. Novo Nordisk CEO, Mike Doustdar, stated in connection with the half-year report on August 5, that approximately 300,000 patients had started on the Wegovy pill in the United Kingdom about three weeks into the launch. The price of Foundayo will, according to Reuters, likely be between 100-120 pounds per month and thus significantly lower than the price of Eli Lilly's injectable drug Mounjaro at 330 pounds.
Hopefully the British market is more informed regarding side effects and limitations of Foundayo, compared to USA, which is of course very biased. But too bad for Novo that they are coming to market so quickly in UK
·13 t sittenI have summarized the week's most important Novo news in this post: https://x.com/investseekers/status/2091573478394667124?s=20
·16 t sitten · MuokattuLower taxes on work, stock income, and entrepreneurship. This will benefit Novo Nordisk employees and other employees in the private labor market. High marginal taxes can reduce the labor supply, because high marginal taxes reduce the gain from working more. Young people in large cities, who cannot afford to enter the housing market, often pay high rent that far exceeds homeowners' ongoing property taxes. Older and already established homeowners can get large, often . tax-advantaged gains on their homes - while tenants do not get equivalent savings. This makes the housing market an effective mechanism and wealth inequality. The owner pays property taxes, but can simultaneously get a large tax-free gain according to the single-family house rule.
You mean that homeowners in the big cities should pay so that the country bumpkins can get a tax cut? Copenhagen already sends millions of kroner to Jutland in equalization and regional development support.
·19 t sittenAt the end of Q2, Novo says they have 1.5 million users of Wygovy pill wordwide. If we assume (conservatively?) that the market has grown to 2 million by the end of 2026, that corresponds to a revenue of 7.8 billion DKK/quarter. That again corresponds to 10% of Novo's full revenue and the beginning of a 2-digit era! Impressive, that Wygovy pill in just 1 year constitutes 10% of Novo's revenue...I will not speculate about final pill prescriptions by the end of 2026. But a significant point for the future is that NN's oral pill active ingredient has enormous background empiricism. It matters that competitors must enter and capture market shares from an opportunity and side effect history already known by doctors. Competitors might perhaps say one has greater weight loss (possibly), but much more than percentages is included in the considerations of prescribers. I know that analysts have a first-generation view on percentages, but that is an outdated view of this market. That's probably why Doustar still isn't writing off Cagrisema. LLY will roughly have to increase their sales x 4 this year, just to catch up a little.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
19 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
3,89%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·10 min sittenNew week, and Nordnet searched searched and ....searched, aren't there any negative comments about Novo Nordisk. Lo and behold, an enterprise Baptista Research, WTF is Baptista. Is it a basement room with 3 prostitutes and 1 pickpocket, that now proclaims Novo SELL and drives the share price down. I know Nordnet doesn't give a damn if the undersigned pulls the plug and uses for example Saxo Bank in the future, but incredibly tired of the way the information flow uncritically reaches all Nordnet's users. Baptista and my bare ass. Damn what a start to the week !!
- ·1 t sittenWildly exciting when the first Foundayo prescription figures are published! Novo Nordisk's American rival Eli Lilly has launched its weight loss pill Foundayo in the United Kingdom. The drug is launched for the treatment of severe obesity and type 2 diabetes, Reuters writes. This is the first European market that Foundayo is entering. The launch comes after Eli Lilly had its pill approved on August 10. Novo had already launched its weight loss tablet, the Wegovy pill, in the British market in July. Novo Nordisk CEO, Mike Doustdar, stated in connection with the half-year report on August 5, that approximately 300,000 patients had started on the Wegovy pill in the United Kingdom about three weeks into the launch. The price of Foundayo will, according to Reuters, likely be between 100-120 pounds per month and thus significantly lower than the price of Eli Lilly's injectable drug Mounjaro at 330 pounds.Hopefully the British market is more informed regarding side effects and limitations of Foundayo, compared to USA, which is of course very biased. But too bad for Novo that they are coming to market so quickly in UK
- ·13 t sittenI have summarized the week's most important Novo news in this post: https://x.com/investseekers/status/2091573478394667124?s=20
- ·16 t sitten · MuokattuLower taxes on work, stock income, and entrepreneurship. This will benefit Novo Nordisk employees and other employees in the private labor market. High marginal taxes can reduce the labor supply, because high marginal taxes reduce the gain from working more. Young people in large cities, who cannot afford to enter the housing market, often pay high rent that far exceeds homeowners' ongoing property taxes. Older and already established homeowners can get large, often . tax-advantaged gains on their homes - while tenants do not get equivalent savings. This makes the housing market an effective mechanism and wealth inequality. The owner pays property taxes, but can simultaneously get a large tax-free gain according to the single-family house rule.You mean that homeowners in the big cities should pay so that the country bumpkins can get a tax cut? Copenhagen already sends millions of kroner to Jutland in equalization and regional development support.
- ·19 t sittenAt the end of Q2, Novo says they have 1.5 million users of Wygovy pill wordwide. If we assume (conservatively?) that the market has grown to 2 million by the end of 2026, that corresponds to a revenue of 7.8 billion DKK/quarter. That again corresponds to 10% of Novo's full revenue and the beginning of a 2-digit era! Impressive, that Wygovy pill in just 1 year constitutes 10% of Novo's revenue...I will not speculate about final pill prescriptions by the end of 2026. But a significant point for the future is that NN's oral pill active ingredient has enormous background empiricism. It matters that competitors must enter and capture market shares from an opportunity and side effect history already known by doctors. Competitors might perhaps say one has greater weight loss (possibly), but much more than percentages is included in the considerations of prescribers. I know that analysts have a first-generation view on percentages, but that is an outdated view of this market. That's probably why Doustar still isn't writing off Cagrisema. LLY will roughly have to increase their sales x 4 this year, just to catch up a little.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
2026 Q2 -tulosraportti
19 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
3,75 DKK/osake
Viimeisin osinko
3,89%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·10 min sittenNew week, and Nordnet searched searched and ....searched, aren't there any negative comments about Novo Nordisk. Lo and behold, an enterprise Baptista Research, WTF is Baptista. Is it a basement room with 3 prostitutes and 1 pickpocket, that now proclaims Novo SELL and drives the share price down. I know Nordnet doesn't give a damn if the undersigned pulls the plug and uses for example Saxo Bank in the future, but incredibly tired of the way the information flow uncritically reaches all Nordnet's users. Baptista and my bare ass. Damn what a start to the week !!
- ·1 t sittenWildly exciting when the first Foundayo prescription figures are published! Novo Nordisk's American rival Eli Lilly has launched its weight loss pill Foundayo in the United Kingdom. The drug is launched for the treatment of severe obesity and type 2 diabetes, Reuters writes. This is the first European market that Foundayo is entering. The launch comes after Eli Lilly had its pill approved on August 10. Novo had already launched its weight loss tablet, the Wegovy pill, in the British market in July. Novo Nordisk CEO, Mike Doustdar, stated in connection with the half-year report on August 5, that approximately 300,000 patients had started on the Wegovy pill in the United Kingdom about three weeks into the launch. The price of Foundayo will, according to Reuters, likely be between 100-120 pounds per month and thus significantly lower than the price of Eli Lilly's injectable drug Mounjaro at 330 pounds.Hopefully the British market is more informed regarding side effects and limitations of Foundayo, compared to USA, which is of course very biased. But too bad for Novo that they are coming to market so quickly in UK
- ·13 t sittenI have summarized the week's most important Novo news in this post: https://x.com/investseekers/status/2091573478394667124?s=20
- ·16 t sitten · MuokattuLower taxes on work, stock income, and entrepreneurship. This will benefit Novo Nordisk employees and other employees in the private labor market. High marginal taxes can reduce the labor supply, because high marginal taxes reduce the gain from working more. Young people in large cities, who cannot afford to enter the housing market, often pay high rent that far exceeds homeowners' ongoing property taxes. Older and already established homeowners can get large, often . tax-advantaged gains on their homes - while tenants do not get equivalent savings. This makes the housing market an effective mechanism and wealth inequality. The owner pays property taxes, but can simultaneously get a large tax-free gain according to the single-family house rule.You mean that homeowners in the big cities should pay so that the country bumpkins can get a tax cut? Copenhagen already sends millions of kroner to Jutland in equalization and regional development support.
- ·19 t sittenAt the end of Q2, Novo says they have 1.5 million users of Wygovy pill wordwide. If we assume (conservatively?) that the market has grown to 2 million by the end of 2026, that corresponds to a revenue of 7.8 billion DKK/quarter. That again corresponds to 10% of Novo's full revenue and the beginning of a 2-digit era! Impressive, that Wygovy pill in just 1 year constitutes 10% of Novo's revenue...I will not speculate about final pill prescriptions by the end of 2026. But a significant point for the future is that NN's oral pill active ingredient has enormous background empiricism. It matters that competitors must enter and capture market shares from an opportunity and side effect history already known by doctors. Competitors might perhaps say one has greater weight loss (possibly), but much more than percentages is included in the considerations of prescribers. I know that analysts have a first-generation view on percentages, but that is an outdated view of this market. That's probably why Doustar still isn't writing off Cagrisema. LLY will roughly have to increase their sales x 4 this year, just to catch up a little.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt